Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.33) by 54.55 percent. This is a 104 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $439.00 thousand which missed the analyst consensus estimate of $1.64 million by 73.25 percent. This is a 82.56 percent decrease over sales of $2.52 million the same period last year.